Sosman J - Search Results

1

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Larkin J, et al. Among authors: sosman j. J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3. J Clin Oncol. 2018. PMID: 28671856 Free PMC article. Clinical Trial.

2

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, et al. Atkins MB, et al. Among authors: sosman ja. J Clin Oncol. 1994 Aug;12(8):1553-60. doi: 10.1200/JCO.1994.12.8.1553. J Clin Oncol. 1994. PMID: 8040667 Clinical Trial.

3

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.

Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, McCloskey T. Stiff PJ, et al. Among authors: sosman ja. J Clin Oncol. 1994 Jan;12(1):176-83. doi: 10.1200/JCO.1994.12.1.176. J Clin Oncol. 1994. PMID: 8270975 Clinical Trial.

4

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J, et al. Sosman JA, et al. J Clin Oncol. 1993 Aug;11(8):1496-505. doi: 10.1200/JCO.1993.11.8.1496. J Clin Oncol. 1993. PMID: 8336188 Clinical Trial.

5

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.

Weiss GR, Margolin KA, Sznol M, Atkins MB, Oleksowicz L, Isaacs R, Sosman JA, Doroshow JH, Trehu EG, Dutcher JP, et al. Weiss GR, et al. Among authors: sosman ja. J Immunother Emphasis Tumor Immunol. 1995 Jul;18(1):52-6. doi: 10.1097/00002371-199507000-00007. J Immunother Emphasis Tumor Immunol. 1995. PMID: 8535571 Clinical Trial. No abstract available.

6

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW 3rd, Fletcher WS, Weiss GR, Unger JM, Sondak VK. Margolin KA, et al. Among authors: sosman ja. J Clin Oncol. 1998 Feb;16(2):664-9. doi: 10.1200/JCO.1998.16.2.664. J Clin Oncol. 1998. PMID: 9469356 Clinical Trial.

7

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH. Sosman JA, et al. Clin Cancer Res. 1997 Jan;3(1):39-46. Clin Cancer Res. 1997. PMID: 9815535 Clinical Trial.

8

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S. Margolin K, et al. Among authors: sosman j. Clin Cancer Res. 1997 Apr;3(4):565-72. Clin Cancer Res. 1997. PMID: 9815721 Clinical Trial.

9

Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.

Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, Sondak VK. Margolin KA, et al. Among authors: sosman ja. J Cancer Res Clin Oncol. 1999;125(5):292-6. doi: 10.1007/s004320050276. J Cancer Res Clin Oncol. 1999. PMID: 10359134 Free article. Clinical Trial.

10

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.

Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Stadler WM, et al. Among authors: sosman j. J Clin Oncol. 1999 Aug;17(8):2541-5. doi: 10.1200/JCO.1999.17.8.2541. J Clin Oncol. 1999. PMID: 10561320 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

436 results

Search Page